Drugs / Vaborbactam
Vaborbactam
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Vaborem | — | 2018-11-20 | europa.eu ↗ |
| Approved | US (FDA) | VABOMERE | — | 2017-08-29 | fda.gov ↗ |
Trials 9
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-07-09 | Menarini Group | Results Menarini Ricerche Announces the Latest Findings of its Vaborem™ and Quofenix™ Clinical Studies menarini.com ↗
Menarini Ricerche, the R&D division of the Menarini Group, announces that it has published four abstracts presenting the latest findings related to its meropenem/vaborbactam (Vaborem ™ ) and delafloxacin (Quofenix ™ ) clinical studies, confirming Menarini’s commitment to fighting life-threatening bacterial infections. |
| 2018-12-20 | Menarini Group | Regulatory The Menarini Group announces meropenem/vaborbactam European marketing authorization menarini.com ↗
Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-07-09 | Menarini Group | Menarini Ricerche Announces the Latest Findings of its Vaborem™ and Quofenix™ Clinical Studies menarini.com ↗ |
| 2018-12-20 | Menarini Group | The Menarini Group announces meropenem/vaborbactam European marketing authorization menarini.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vaborbactam | “Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects.” PMID 27527080 ↗ Sep 2016 |
| Known as | RPX7009 | “Vaborbactam (formerly RPX7009) is a member of a new class of β-lactamase inhibitor with pharmacokinetic properties similar to those of many β-lactams, including carbapenems.” PMID 27527080 ↗ Sep 2016 |
| Known as | Vaborbactam component of carbavance | ChEMBL registry synonym — accepted as the source's own label CHEMBL3317857 ↗ |
| Known as | Vaborbactam component of vabomere | ChEMBL registry synonym — accepted as the source's own label CHEMBL3317857 ↗ |
| Action | Inhibit | “Vaborbactam (formerly RPX7009) is a member of a new class of β-lactamase inhibitor with pharmacokinetic properties similar to those of many β-lactams, including carbapenems.” PMID 27527080 ↗ Sep 2016 |
| Modality | Small molecule | — CHEMBL3317857 ↗ |
| Route | Intravenous | “Intravenous Biapenem and RPX7009, administered alone and in combination” NCT01772836 ↗ |